Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain

Condition:   Acute-onset Herpes Zoster PainInterventions:   Drug: CNTX-2022 (lidocaine gel, 40%);   Drug: PlaceboSponsor:   Centrexion TherapeuticsTerminated - verified February 2016

Source: ClinicalTrials.gov - February 9, 2015 Category: Research Source Type: clinical trials